Publication date: Dec 21, 2024
No currently approved treatment for pediatric plaque psoriasis selectively targets interleukin (IL)-23. In adults, guselkumab (a selective IL-23 inhibitor targeting the p19 subunit) demonstrated substantial efficacy with a favorable safety profile in treating moderate-to-severe plaque psoriasis. PROTOSTAR (NCT03451851) evaluated the efficacy and safety of guselkumab in pediatric patients with moderate-to-severe plaque psoriasis. This phase 3, randomized, placebo-controlled study enrolled patients ≥6 to
| Concepts | Keywords |
|---|---|
| Dermatol | Controlled |
| Drugs | Efficacy |
| Efficacy | Guselkumab |
| Nct03451851 | Il |
| Pediatric | Moderate |
| Pediatric | |
| Phase | |
| Placebo | |
| Plaque | |
| Protostar | |
| Psoriasis | |
| Randomized | |
| Safety | |
| Severe | |
| Treatment |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Guselkumab |
| disease | MESH | psoriasis |
Original Article
(Visited 1 times, 1 visits today)